Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex

NCT ID: NCT03389308

Last Updated: 2020-09-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 51 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-12-01
• Study Completion Date: 2020-04-17

Brief Summary

The primary objective of this study is to evaluate the long term safety and tolerability of diacerein 1% ointment for 2 treatment cycles in subjects with EBS that previously participated in the CCP-020-301 or the CCP-020-101 studies.

Detailed Description

This is an international, multicenter, open-label, long term extension study evaluating the safety of topical Diacerein 1% Ointment for the treatment of subjects with EBS. At Visit 1, EBS subjects who completed the CCP-020-301 double-blind safety and efficacy study or participated in the CCP-020-101 PK study (feeder studies) who meet all the inclusion/exclusion criteria will be eligible to complete 2 treatment cycles of CCP-020.

Each treatment cycle will consist of 8 weeks on treatment (once-daily, at home study medication applications) followed by 8 weeks off treatment (only Investigator approved bland, non-medicated emollient/moisturizer, routine cleansing products and sunscreens) with a maximum of 2 treatment cycles allowed for up to 52 weeks.

At Baseline Visit (corresponding to the final study visit of the feeder study), the investigator will perform a clinical assessment and determine if any of the subject's lesions require treatment (up to 30% BSA). If the subject has active lesions as determined by the Investigator's clinical assessment, the subject will initiate a cycle of once-daily, at home study medication application to their EBS lesions for 8 weeks (treatment period) followed by an 8-week period where no treatment will be administered. Subjects presenting with no active lesions (as determined by the Investigator's clinical assessment) will not begin treatment and instead, will be instructed to return to the clinic for re-evaluation in 8 weeks or upon worsening of EBS lesions, whichever happens first.

Conditions

Epidermolysis Bullosa; Epidermolysis Bullosa Simplex

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment period

Subjects with active lesions as determined Investigator's clinical assessment, will initiate a cycle of applying diacerein 1% ointment once-daily, study medication, at home to their EBS lesions for 8 weeks.

Following the Treatment Period, subjects will go Off Treatment for 8 weeks using only investigator approved bland, non-medicated emollient/moisturizer, routine cleansing products and sunscreens. As determined Investigator's clinical assessment, subjects may enter into another Treatment Period of 8 weeks.

The duration of a subject's participation in the extension study may be as short as 32 weeks or as long as 52 weeks depending on the cycle initiation schedule for each individual subject.

Group Type: EXPERIMENTAL

diacerein 1% ointment

Intervention Type: DRUG

Topically apply study medication to lesions identified by the Investigator that require.

treatment

Interventions

diacerein 1% ointment

Topically apply study medication to lesions identified by the Investigator that require.

treatment

Intervention Type: DRUG

Other Intervention Names

CCP-020

Eligibility Criteria

Inclusion Criteria

• The subject is capable of understanding and complying with protocol requirements.
• The subject or the subject's legally acceptable representative signs and dates a written, informed consent/assent form and any required privacy authorization prior to the initiation of any study procedures.
• Subject has a documented genetic mutation consistent with EBS.
• Subject has completed study CCP-020-301 or participated in study CCP-020-101.
• Subject/caregiver agrees to report use of any topical therapies applied to EBS lesions
• If the subject is a woman of childbearing potential, she has a negative urine pregnancy test and agrees to use an approved effective method of birth control, for the duration of the study.
• Subject is non-lactating and is not planning for pregnancy during the study period.
• Subject is willing and able to follow all study instructions and to attend all study visits.

Exclusion Criteria

• Subject has EBS lesions to be treated that are infected
• Subject has evidence of a systemic infection or has used systemic antibiotics within 7 days prior to Baseline Visit.
• The subject was discontinued from the feeder study due to an adverse event judged to be related or possibly related to the study medication.
• Subject has experienced a change in clinical status from the feeder study that puts the subject at undue risk to participate.

• Minimum Eligible Age: 6 Months
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Castle Creek Pharmaceuticals, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mary Spellman, MD

Role: STUDY_CHAIR

Castle Creek Pharmaceuticals

Locations

Ann and Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

University of North Carolina (UNC) - Chapel Hill

Chapel Hill, North Carolina, United States

Children's Hospital of San Antonio

San Antonio, Texas, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

CCP-020-302

Identifier Type: -

Identifier Source: org_study_id